OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $17.5714.

A number of research firms have commented on OPRX. Lake Street Capital reduced their price objective on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Stifel Nicolaus dropped their target price on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Zacks Research upgraded shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, March 13th. Stephens reduced their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Finally, Roth Mkm decreased their price objective on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 6th.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $6.56 on Friday. The stock’s fifty day simple moving average is $8.18 and its 200 day simple moving average is $13.28. The stock has a market capitalization of $123.07 million, a price-to-earnings ratio of 25.23 and a beta of 1.28. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a 52-week low of $5.54 and a 52-week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. As a group, sell-side analysts forecast that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx announced that its Board of Directors has initiated a stock repurchase plan on Thursday, March 5th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Institutional Trading of OptimizeRx

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new position in shares of OptimizeRx during the fourth quarter valued at $535,000. Inspire Investing LLC purchased a new stake in OptimizeRx in the 4th quarter worth about $1,175,000. Engineers Gate Manager LP acquired a new stake in OptimizeRx during the 4th quarter worth about $228,000. Boothbay Fund Management LLC grew its stake in OptimizeRx by 53.1% during the 4th quarter. Boothbay Fund Management LLC now owns 73,488 shares of the company’s stock valued at $901,000 after acquiring an additional 25,502 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in OptimizeRx by 16.9% during the 4th quarter. Bridgeway Capital Management LLC now owns 69,029 shares of the company’s stock valued at $846,000 after acquiring an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.